Clinical Trials Collective Data Reference 
The Cannigma
APRIL 12, 2023
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 1, 2021
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. About RYAH Group, Inc. RYAH Group, Inc.
Cannabis Law Report
DECEMBER 14, 2021
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Cannabis Law Report
JUNE 30, 2021
In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Building the Data Backend. Mental Health Challenges. Psychedelics could offer a better alternative for many patients. MedXtractor Corp.
Cannabis Law Report
JULY 28, 2021
The ideal RPS has a strong technical background and is comfortable learning and navigating the online systems unique to various regulatory agencies, as well as other specialized technologies for research, clinical trials and project management. Experience working for a clinical study Sponsor. A master’s degree is preferred.
Expert insights. Personalized for you.
133 
Let's personalize your content